Clinical Trial Update: To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Humira (adalimumab) in subjects with moderate to severe hidradenitis suppurativa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Florida Academic Dermatology Centers | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED